Ebb & Flow

Sequenom (NASDAQ:SQNM) has more than quadrupled its market cap to $1.6 billion from $350 million since early June, when the company released initial data on its Down syndrome test.

The $1.2 billion uptick equates to $436 for each of the 2.8 million U.S. women screened annually by the current method...